<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04631653</url>
  </required_header>
  <id_info>
    <org_study_id>SE20294A</org_study_id>
    <nct_id>NCT04631653</nct_id>
  </id_info>
  <brief_title>Verisee Software for Diabetic Retinopathy Screening</brief_title>
  <official_title>The Clinical Benefit of an Artificial Intelligence Software Implementation on Diabetic Retinopathy Screening</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taichung Veterans General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taichung Veterans General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators aim to improve the diagnostic accuracy and the clinical referral rate for&#xD;
      diabetic retinopathy by using a deep learning-based software.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Diabetic retinopathy (DR) is the leading cause of blindness among working-age patients with&#xD;
      type 2 diabetes. According to previous studies, early screening and timely treatment can&#xD;
      reduce the risk of worsening DR and blindness. International guidelines recommend that&#xD;
      screening for DR be performed at least once every year for patients with type 2 diabetes. The&#xD;
      investigators will implement a validated deep learning-based software, VeriSee®, in clinics,&#xD;
      and evaluate the benefits on diagnostic accuracy and the clinical referral rate for diabetic&#xD;
      retinopathy after implementation of this software.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Examine the diagnostic accuracy in referred participants</intervention_model_description>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>diagnostic accuracy</measure>
    <time_frame>12 months</time_frame>
    <description>diagnostic accuracy compared to the baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Screening rate of diabetic retinopathy</measure>
    <time_frame>12 months</time_frame>
    <description>Screening rate of diabetic retinopathy in patients with diabetes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in HbA1c</measure>
    <time_frame>3 months</time_frame>
    <description>Changes in HbA1c</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Referral rate of diabetic retinopathy</measure>
    <time_frame>12 months</time_frame>
    <description>Successful referral rate for referrable diabetic retinopathy</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Diabetic Retinopathy</condition>
  <arm_group>
    <arm_group_label>Verisee</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Screening diabetic retinopathy using Verisee software</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>VeriSee®</intervention_name>
    <description>Screening of diabetic retinopathy using a validated deep learning-based software,VeriSee®</description>
    <arm_group_label>Verisee</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults&#xD;
&#xD;
          -  Patients with diabetes&#xD;
&#xD;
          -  Cooperation to fundal scopic examination&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diabetic duration &lt; 5 years in patients with type 1 diabetes&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>I-Te Lee, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Taichung Veterans General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>I-Te Lee, MD,PhD</last_name>
    <phone>+886-4-23592525</phone>
    <phone_ext>3070</phone_ext>
    <email>itlee@vghtc.gov.tw</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yu-Hsuan Li, MD</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Division of Endocrinology and Metabolism in Taichung Veterans General Hospital</name>
      <address>
        <city>Taichung</city>
        <zip>407</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>October 18, 2020</study_first_submitted>
  <study_first_submitted_qc>November 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2020</study_first_posted>
  <last_update_submitted>November 15, 2020</last_update_submitted>
  <last_update_submitted_qc>November 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Diabetic Retinopathy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

